Non-Current Liabilities
Contingent Consideration Liability (Non-Current)
Vertex Pharmaceuticals Contingent Consideration Liability (Non-Current) decreased by 2.4% to $78.10M in Q3 2025 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $78.10M to $78.10M. Over 4 years (FY 2020 to FY 2024), Contingent Consideration Liability (Non-Current) shows a downward trend with a -20.2% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2022
Last reportedQ4 2025
How to read this metric
An increase often indicates successful integration or high performance of acquired assets triggering earn-outs, while a decrease may signal missed targets or the settlement of obligations.
Detailed definition
This represents the long-term portion of obligations to pay additional consideration to sellers in connection with past...
Peer comparison
Standard for companies with active M&A strategies and earn-out structures in purchase agreements.
Metric ID:
contingent_consideration_liability_noncurrentHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $187.30M | $188.50M | $186.50M | $179.00M | $129.80M | $127.20M | $129.00M | $127.10M | $126.50M | $127.70M | $77.40M | $77.30M | $77.80M | $78.10M | $76.90M | $79.10M | $80.00M | $78.10M |
| QoQ Change | — | +0.6% | -1.1% | -4.0% | -27.5% | -2.0% | +1.4% | -1.5% | -0.5% | +0.9% | -39.4% | -0.1% | +0.6% | +0.4% | -1.5% | +2.9% | +1.1% | -2.4% |
| YoY Change | — | — | — | — | -30.7% | -32.5% | -30.8% | -29.0% | -2.5% | +0.4% | -40.0% | -39.2% | -38.5% | -38.8% | -0.6% | +2.3% | +2.8% | +0.0% |
Range$76.90M – $188.50M
CAGR-18.6%
Avg YoY Growth-19.8%
Median YoY Growth-29.8%
Contingent Consideration Liability (Non-Current) at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's contingent consideration liability (non-current)?
- Vertex Pharmaceuticals (VRTX) reported contingent consideration liability (non-current) of $78.10M in Q3 2025.
- How has Vertex Pharmaceuticals's contingent consideration liability (non-current) changed year-over-year?
- Vertex Pharmaceuticals's contingent consideration liability (non-current) decreased by 0.0% year-over-year, from $78.10M to $78.10M.
- What is the long-term trend for Vertex Pharmaceuticals's contingent consideration liability (non-current)?
- Over 4 years (2020 to 2024), Vertex Pharmaceuticals's contingent consideration liability (non-current) has grown at a -20.2% compound annual growth rate (CAGR), from $189.60M to $76.90M.
- What does contingent consideration liability (non-current) mean?
- The estimated long-term debt owed to sellers of acquired companies based on future performance targets.